Telixu |

THE TELIXU MEDICAL EDUCATION SITE IS CURRENTLY UNDER CONSTRUCTION

REMINDER: THIS FORM IS INTENDED FOR AUSTRALIAN HEALTHCARE PROFESSIONALS ONLY.

Please complete the form below if would like Telix to contact you regarding TelixU. Your contact information will not be used for any other purpose than for a representative to advise you of when the Australian TelixU Medical Education site is live. Expected live date is July 1, 2022.

First Name *

Last Name *

Work Email Address *

Phone Number

Organisation

Job Title

Areas of Interest Areas of Interest I'd like to be notfied when the telixu.com.au website is live

Other Other Illuccix® (TLX591-CDx, 68Ga-PSMA-11 for prostate cancer imaging) ProstACT Study (TLX591, 177Lu-DOTA-rosopatamab for prostatecancer therapy) IPAX Study (TLX101, 131I-IPA for glioblastoma therapy) CUPID Study(TLX592, 64Cu / 225Ac-RADmAb for prostate cancer imaging/therapy)

© 2022 Telix Pharmaceuticals (ANZ) Pty Ltd.
Suite 401, 55 Flemington Road, North Melbourne, VIC 3051.
The Telix Pharmaceuticals and Illuccix name and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates. All rights reserved. AU-ILL-2200007. May 2022.